文献速递帕金森病与运动障碍

针对前驱期帕金森病临床试验设计的统计学考量

Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease.
PubMed 文献 · Neurology · 2022-01-01

本文讨论前驱期帕金森病临床试验的设计与统计考量,提出涵盖2a期、2b期和3期的三种试验设计模板,并指出短期内需明确表型转化定义和验证中间终点,长期需采用适应性试验设计、主方案和研究注册库以加速疗法开发。

要点

  • 提出2a期三臂短期概念验证试验,探索前驱期患者运动结局变化。
  • 提出2b期以多巴胺转运体成像特异性结合比年变化为主要结局,表型转化为关键次要结局。
  • 提出3期大型简单设计,采用营养品或行为干预远程给药,表型转化为主要结局。

核心结论

  • 前驱期帕金森病临床试验有望保护神经元功能、延缓或阻止进展为临床帕金森病。
  • 短期内需要明确且可能因情境而异的表型转化定义,并验证中间终点。
  • 长期使用适应性试验设计、主方案和研究注册库有助于加速疗法开发。

研究设计与样本

  • 本文为方法学论述,提出三种前驱期帕金森病临床试验设计模板,未报告样本量。

主要发现

  • 2a期试验为三臂短期设计,聚焦靶点结合的概念验证,并在已表现出无症状但可测量运动功能障碍的前驱期亚组中探索运动结局变化。
  • 2b期试验建议以多巴胺转运体成像特异性结合比每年评估、持续2年的进展为主要结局,表型转化为关键次要结局。
  • 3期试验为大型简单设计,采用营养品或行为干预远程给药,表型转化为主要结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials testing interventions for prodromal Parkinson disease (PD) hold particular promise for preserving neuronal function and thereby slowing or even forestalling progression to overt PD. Selection of the appropriate target population and outcome measures presents challenges unique to prodromal PD. We propose 3 clinical trial designs, spanning phase 2a, phase 2b, and phase 3 development, that might serve as templates for prodromal PD trials. The proposed phase 2a trial is of a 3-arm design of short duration and focuses on proof of concept with respect to target engagement and change in a motor outcome in a subset of prodromal participants who already manifest asymptomatic but measurable motor dysfunction as an exploratory aim. The proposed phase 2b trial suggests progression of dopamine transporter imaging specific binding ratio as a primary outcome evaluated annually over 2 years with phenoconversion to PD as a key secondary outcome. The proposed phase 3 trial is a large, simple design of a nutraceutical or behavioral intervention with remote administration and phenoconversion as the primary outcome. We then consider what additional data are needed in the short term to better design prodromal PD trials and examine what longer-term goals would accelerate discovery of safe and effective therapies for individuals at risk of PD. Clear and potentially context-specific definitions of phenoconversion and validation of intermediate endpoints are needed in the short term. The use of adaptive trial designs, master protocols, and research registries would help accelerate therapy development in the long term.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Macklin EA, Coffey CS, Brumm MC, et al. Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease. Neurology. 2022. PMID: 35970588. doi:10.1212/WNL.0000000000200897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。